NCT07498920Not yet recruiting
Gut Microbiome in DLBCL Treated With Glofitamab
Role of the Gut Microbiome in the Outcome of Diffuse Large B-Cell Lymphoma Patients Treated With Glofitamab
Source: ClinicalTrials.gov · Last updated 27 Mar 2026
Brief summary (registry, in English)
The gut microbiome (GM) has recently emerged as one of the key modifiable factors of response and prognosis to immunotherapy in cancer patients. Currently, it is unknown if GM also modulates anti-tumor responses to T cell engagers (TCE) including glofitamab in DLBCL patients.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 30 (estimated)
- First submitted
- 23 Mar 2026
- Start date
- 1 Apr 2026
- Primary completion date
- 1 Apr 2029
- Lead sponsor
- Peking Union Medical College Hospital
- NCT number
- NCT07498920
What you commit to
- Study type: Observational
- Planned participants: 30
- From 1 Apr 2026 to the primary completion date, 1 Apr 2029
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Evidence of significant, uncontrolled concomitant diseases that could affect compliance with the protocol or interpretation of results.
- Concurrent second malignancy.
Who the study is looking for
- Histologically/cytologically confirmed diagnosis of DLBCL
- Is being planned to received Glofitamab
- Be able to provide written informed consent
Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.